BACKGROUND: The most common, potentially fatal complication following an acute myocardial infarction (AMI) is early ventricular fibrillation (EVF). According to the guidelines, the assessment of implanting an implantable cardioverter defibrillator (ICD) is sufficient 6 weeks after the event, in patients with reduced left ventricular ejection fraction (LVEF), regardless of VF. The present study aimed to evaluate the 6-week prognosis of patients surviving an EVF. We divided the patients in two group based on their general condition at the time they left the hospital. We investigated the clinical characteristics of patients discharged in good general health but still dying within 6 weeks. METHODS: The present study comprised 12,270 patients with AMI following their primary revascularization in the first 12 h of symptom onset. Five hundred and forty-seven of them suffered EVF due to the AMI. Clinical and 6-week mortality data were examined. RESULTS: Poor general condition correlates with multiple comorbidities, higher troponin levels, more severe complications after the event. Patients leaving in good condition thought to be low risk, from dying. But low LVEF, high blood sugar, high cardiac biomarker level, poor renal function elevates the risk of dying within 6 weeks. However, there is no difference in clinical characteristics between EVF- cases and EVF+ cases in good condition who dies within 6 weeks. CONCLUSIONS: According to our study we can select patients who are safe in the critical 6-week period and those who need closer follow-up despite leaving in good general condition. 2021 Quantitative Imaging in Medicine and Surgery. All rights reserved.
BACKGROUND: The most common, potentially fatal complication following an acute myocardial infarction (AMI) is early ventricular fibrillation (EVF). According to the guidelines, the assessment of implanting an implantable cardioverter defibrillator (ICD) is sufficient 6 weeks after the event, in patients with reduced left ventricular ejection fraction (LVEF), regardless of VF. The present study aimed to evaluate the 6-week prognosis of patients surviving an EVF. We divided the patients in two group based on their general condition at the time they left the hospital. We investigated the clinical characteristics of patients discharged in good general health but still dying within 6 weeks. METHODS: The present study comprised 12,270 patients with AMI following their primary revascularization in the first 12 h of symptom onset. Five hundred and forty-seven of them suffered EVF due to the AMI. Clinical and 6-week mortality data were examined. RESULTS: Poor general condition correlates with multiple comorbidities, higher troponin levels, more severe complications after the event. Patients leaving in good condition thought to be low risk, from dying. But low LVEF, high blood sugar, high cardiac biomarker level, poor renal function elevates the risk of dying within 6 weeks. However, there is no difference in clinical characteristics between EVF- cases and EVF+ cases in good condition who dies within 6 weeks. CONCLUSIONS: According to our study we can select patients who are safe in the critical 6-week period and those who need closer follow-up despite leaving in good general condition. 2021 Quantitative Imaging in Medicine and Surgery. All rights reserved.
Entities:
Keywords:
Early ventricular fibrillation (EVF); acute myocardial infarction (AMI); prognosis
Authors: Franz-Josef Neumann; Miguel Sousa-Uva; Anders Ahlsson; Fernando Alfonso; Adrian P Banning; Umberto Benedetto; Robert A Byrne; Jean-Philippe Collet; Volkmar Falk; Stuart J Head; Peter Jüni; Adnan Kastrati; Akos Koller; Steen D Kristensen; Josef Niebauer; Dimitrios J Richter; Petar M Seferovic; Dirk Sibbing; Giulio G Stefanini; Stephan Windecker; Rashmi Yadav; Michael O Zembala Journal: Eur Heart J Date: 2019-01-07 Impact factor: 29.983
Authors: Meena Zareh; Jeffrey J Rade; Joseph L Thomas; Atman Shah; Ankush Chhabra; Jordan Prutkin; Zach Shinar; Michael Abraham; Nathan Deal; Dick Kuo; David Pearson; Lee Garvey; David Lange; Timothy D Henry; Shoma Desai; Henry Kim; Stuart Swadron; Han Tun; David M Shavelle Journal: J Invasive Cardiol Date: 2020-01-15 Impact factor: 2.022
Authors: Scott D Solomon; Steve Zelenkofske; John J V McMurray; Peter V Finn; Eric Velazquez; George Ertl; Adam Harsanyi; Jean L Rouleau; Aldo Maggioni; Lars Kober; Harvey White; Frans Van de Werf; Karen Pieper; Robert M Califf; Marc A Pfeffer Journal: N Engl J Med Date: 2005-06-23 Impact factor: 91.245
Authors: Silvia G Priori; Carina Blomström-Lundqvist; Andrea Mazzanti; Nico Blom; Martin Borggrefe; John Camm; Perry Mark Elliott; Donna Fitzsimons; Robert Hatala; Gerhard Hindricks; Paulus Kirchhof; Keld Kjeldsen; Karl-Heinz Kuck; Antonio Hernandez-Madrid; Nikolaos Nikolaou; Tone M Norekvål; Christian Spaulding; Dirk J Van Veldhuisen Journal: Eur Heart J Date: 2015-08-29 Impact factor: 29.983
Authors: G H Tofler; P H Stone; J E Muller; J D Rutherford; S N Willich; N F Gustafson; W K Poole; B E Sobel; J T Willerson; T Robertson Journal: Am J Cardiol Date: 1987-10-01 Impact factor: 2.778
Authors: Gerhard Steinbeck; Dietrich Andresen; Karlheinz Seidl; Johannes Brachmann; Ellen Hoffmann; Dariusz Wojciechowski; Zdzisława Kornacewicz-Jach; Beata Sredniawa; Géza Lupkovics; Franz Hofgärtner; Andrzej Lubinski; Mårten Rosenqvist; Alphonsus Habets; Karl Wegscheider; Jochen Senges Journal: N Engl J Med Date: 2009-10-08 Impact factor: 91.245